BGP TRACP-5b BGP TRACP-5b P 0.05

()2014 10 8 20 Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No.20 3615 OP 2011 1 2013 6 120 OP 3 40 37 40 38 40 38 BMD BGP-5b TRACP-5b OP 1 4 L1 4NFTH BMD BGP TRACP-5b P 0.05 OP L1 4 NF TH BMD BGP TRACP-5b P 0.05 L1 4 NF TH BMD BGP TRACP-5b P 0.05 BMD BGP TRACP-5b P 0.05 P 0.05 OP Effect value of calcitonin combined with alendronate on the osteoporosis Hu Yongyou. Department of Surgery, The People s Hospital of Yongchuan District, Chongqing 402160, China Email: zzzj73@sina.com AbstractObjective To observe the curative effect of calcitonin combined with alendronate on the osteoporosis (OP). Methods 120 patients with OP were selected from Jan 2011 to Jun 2013. They could be divided into three groups in order. The control group (n=40, the actual completion of 37 cases) was in calcitonin, the control group (n=40, the actual completion of 38 cases) was in alendronate, and the observation group (n=40, the actual completion of 38 cases) was in calcitonin combined with alendronate to compare the bone density (BMD), serum osteocalcin (BGP), tartrate resistant acid phosphatase-5b (TRACP-5b), pain symptoms, quality of life and untoward effect. Results Compared with the pretherapy, the lumbar vertebrae 1-4 (L1-4), neck of femur (NF), total hip (TH)'s BMD and scores of quality of life were significantly increased, and the BGP, TRACP-5b were significantly decreased after the treatment. There were significant differences between the groups (P<0.05). There were no significant differences in the L1-4, NF, TH s BMD, BGP, TRACP-5b and scores of quality of life between the groups in the pretherapy (P>0.05). Compared with the control group and control group, the L1-4, NF, TH s BMD and scores of quality of life (in addition to physiological functions) in the observation group were significantly higher, the BGP and TRACP-5b were significantly lower, and the pain symptoms were significantly better. There were significant differences between the groups (P<0.05). There were no significant differences between the control group and control group (P>0.05) in BMD, BGP, DOI:10.3877/cma.j.issn.1674-0785.2014.20.007 402160 Email: zzzj73@sina.com

3616 ()2014 10 8 20 Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No.20 TRACP-5b, pain symptoms and scores of quality of life. There were no significant differences in the untoward effect between the three groups (P>0.05). Conclusion Calcitonin combined with alendronate for the OP, is safe, effective and worthy of popularization and application. Key wordsosteoporosis; Calcitonin; Bone density; Alendronate; Osteodynia osteoporosis OP [1] [2] 2050 50 5 908 000 48 500 000 50% [3] OP OP 1. 2011 1 2013 6 120 OP 2011 [4] 1 4 L1 4 NF Ward BMD BMD 2.5 AKP BGP OP 1 6 OP 2. 1 2 3 1 2 3 120 OP 3 40 Novartis Pharma Schweiz AG. Switzerland H20090459 1 ml 50 IU50 IU/1 /d 1 1 1 1 / 40 J20080073 70 mg/1 /1 / 30 min 40 50 IU/1 /d 1 1 1 1 / 1 /1 / 30 min D 3 D H10950029 600 mg/ 1 /1 /d H20030491 0.25 μg/1 /1 /d 1 3. 1 1 BMD X EXPERT-XL LUNAR L1 4 NF TH BMD2 BGP -5b TRACP-5b ELISA3 VAS 0 10 [5] 2 1 2 1 4 SF-36 3 0 100 5 4. SPSS 19.0 [% ] χ 2 x s t α 0.05 P 0.05 1. 3 1 2 37 15 22

()2014 10 8 20 Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No.20 3617 66.7 8.93.2 1.9 2 1 1 38 17 21 67.6 8.43.3 2.5 2 1 38 15 23 67.9 7.4 2.9 2.1 OP P 0.05 2. BMD 1 2 OP L1 4 NF TH BMD P 0.05 OP L1 4 NF TH BMD P 0.05 L1 4 NF TH BMD P 0.05 P 0.05 3. 3 4 OP BGP TRACP-5b P 0.05 OP BGP TRACP-5b P 0.05 BGP TRACP-5b P 0.05 P 0.05 4. 5 P 0.05 P 0.05 67.6% 52.6% 92.1% 5. 6 7 OP P 0.05 OP P 0.05 OP BMD g/m 2 x s L 1 4 NF TH t P t P t P 37 0.652±0.08 0.745±0.09 4.698 0.000 0.564±0.05 0.675±0.06 8.645 0.000 0.593±0.06 0.702±0.06 7.814 0.000 38 0.665±0.07 0.751±0.08 4.987 0.000 0.573±0.07 0.679±0.08 6.147 0.000 0.592±0.06 0.709±0.05 9.234 0.000 38 0.662±0.08 0.786±0.07 7.191 0.000 0.568±0.07 0.719±0.07 9.403 0.000 0.597±0.06 0.744±0.08 9.062 0.000 OP BMD L 1 4 0.750 0.456 0.541 0.590 0.174 0.862 NF 0.639 0.525 0.284 0.777 0.311 0.757 TH 0.072 0.943 0.289 0.773 0.363 0.718 L 1 4 0.305 0.761 2.206 0.030 2.030 0.046 NF 0.245 0.807 2.929 0.005 2.320 0.024 TH 0.550 0.584 2.567 0.012 2.287 0.025 OP BGP TRACP-5b x s BGP(ng/ml) TRACP-5b(U/L) t P t P 37 23.99±4.94 21.54±4.99 2.122 0.037 3.37±1.26 2.68±1.67 2.006 0.049 38 24.12±5.06 20.78±5.40 2.782 0.007 3.38±1.34 2.64±1.78 2.047 0.044 38 23.87±4.84 17.67±6.35 4.787 0.000 3.36±1.46 1.97±1.02 4.811 0.000 OP BGP TRACP-5b BGP 0.113 0.910 0.106 0.916 0.220 0.826 TRACP-5b 0.033 0.974 0.032 0.975 0.062 0.951 BGP 0.633 0.529 2.930 0.005 2.300 0.024 TRACP-5b 0.100 0.921 2.229 0.029 2.013 0.048

3618 ()2014 10 8 20 Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No.20 OP 37 16 9 12 38 10 10 18 38 23 12 3 Z= 1.583 P=0.113Z= 2.094 P=0.036Z= 3.781 P=0.000 OP x s t P t P t P 37 54.72±12.80 60.47±10.36 2.124 0.037 62.88±11.12 71.11±8.89 3.516 0.001 23.79±22.10 33.81±20.54 2.020 0.047 38 55.21±11.42 61.11±10.22 2.373 0.020 64.03±10.22 70.01±8.21 2.812 0.006 24.28±23.88 34.49±20.31 2.008 0.048 38 54.89±12.01 65.99±9.94 4.389 0.000 63.86±11.37 75.33±8.26 4.838 0.000 24.04±23.17 40.22±19.55 3.290 0.002 OP SF-36 0.175 0.862 0.059 0.953 0.119 0.906 0.467 0.612 0.377 0.707 0.069 0.451 0.092 0.927 0.048 0.962 0.045 0.964 0.269 0.789 2.355 0.021 2.110 0.038 0.557 0.579 2.130 0.036 2.816 0.006 0.144 0.886 1.385 0.170 1.275 0.206 P 0.05 P 0.05 6. 5 13.5% 5 13.2% 6 15.8% χ 2 0.127 P 0.938 3 8.1%3 7.9% 0 0 χ 2 3.212 P 0.201 [6] OP OP OP OP [1] OP OP [7] OP CT OP BMD BGP TRACP-5b OP 1 000 [8]

()2014 10 8 20 Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No.20 3619 BMD [9] CT 32 BMD CT β- Ca 2+ β- [10] 67.6% 52.6% OP L1 4 NF TH BMD BGP TRACP-5b P 0.05 P 0.05 P 0.05 [5] BMD L1 4 NF TH [8] BGP TRACP-5b BGP TRACP-5b BMD OP [11] CT 2 3 [1],. [J]., 2013, 12(5): 397-400. [2] Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis related fractures in the United States, 2005-2025[J]. J Bone Miner Res, 2007, 22(3): 465-475. [3]. [J]., 2009, 3(3): 148-154. [4]. (2011 )[J]., 2011, 4(1): 2-17. [5],,. [J]., 2011, 2(3): 36-37. [6] Silverman S, Christiansen C. Individualizing osteoporosis therapy[j]. Osteoporos Int, 2012, 23(3): 797-809. [7] Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis[j]. J Pharmacol Exp Ther, 2010, 333(1): 2-13. [8],,. [J]., 2012, 33(15): 16-19. [9] Karsdal MA, Henriksen K, Bay-Hensen AC, et al. Lessons learned from the development of oral calcitonin: The first tablet formulation of a protein in phase clinical trials[j]. J Clin Pharmacol, 2011, 51(4): 460-471. [10],,,. [J]., 2009, 23(4): 279-281. [11]. [J]., 2010, 18(8): 1188-1189. 2014-08-06. J/CD. 2014 8 203615-3619.